Short Interest in Invesco Pharmaceuticals ETF (NYSEARCA:PJP) Expands By 2,312.6%

Invesco Pharmaceuticals ETF (NYSEARCA:PJP) was the recipient of a large growth in short interest during the month of June. As of June 15th, there was short interest totaling 16,116 shares, a growth of 2,312.6% from the May 31st total of 668 shares. Based on an average daily volume of 18,819 shares, the short-interest ratio is presently 0.9 days. Approximately 0.5% of the shares of the stock are sold short.

Invesco Pharmaceuticals ETF Stock Performance

PJP stock opened at $115.68 on Friday. The stock’s 50 day moving average price is $108.51 and its 200 day moving average price is $106.63. The firm has a market cap of $378.27 million, a P/E ratio of 15.59 and a beta of 0.46. Invesco Pharmaceuticals ETF has a 1 year low of $79.47 and a 1 year high of $117.09.

Institutional Trading of Invesco Pharmaceuticals ETF

A number of large investors have recently made changes to their positions in the stock. WBI Investments LLC acquired a new position in shares of Invesco Pharmaceuticals ETF in the third quarter valued at approximately $499,000. HBW Advisory Services LLC acquired a new stake in Invesco Pharmaceuticals ETF during the fourth quarter worth approximately $533,000. Northwestern Mutual Wealth Management Co. boosted its position in Invesco Pharmaceuticals ETF by 829.5% during the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 25,941 shares of the company’s stock worth $2,712,000 after acquiring an additional 23,150 shares during the last quarter. Gilpin Wealth Management LLC purchased a new stake in Invesco Pharmaceuticals ETF in the 4th quarter worth approximately $735,000. Finally, GRIMES & Co WEALTH MANAGEMENT LLC purchased a new stake in Invesco Pharmaceuticals ETF in the 4th quarter worth approximately $502,000.

Invesco Pharmaceuticals ETF Company Profile

PowerShares Dynamic Pharmaceuticals Portfolio (the Fund) is a non-diversified fund. The Fund seeks investment results that correspond generally to the price and yield of the Dynamic Pharmaceuticals Intellidex Index (the Index). The Index evaluates companies based on a variety of investment merit criteria, including fundamental growth, stock valuation, investment timeliness and risk factors. The Index consists of stocks of 30 United States pharmaceutical companies. These are companies that are principally engaged in the research, development, manufacture, sale or distribution of pharmaceuticals and drugs of all types.